Search results for "Vaccines"
Treating sickle cell, managing COPD, more stories
This issue covers stories on sickle cell disease, chronic obstructive pulmonary disease, and other stories.
https://immattersacp.org/archives/2024/04/treating-sickle-cell-managing-copd-more-stories.htm
1 Apr 2024
Modeling study finds RSV vaccines cost-effective for older U.S. adults
Vaccination programs using the monovalent adjuvanted or bivalent vaccine against respiratory syncytial virus (RSV) were projected to be potentially cost-effective at a price per dose of up to $127 or up to $118, respectively, over a first RSV season.
https://immattersacp.org/weekly/archives/2023/12/05/4.htm
5 Dec 2023
ACP urges adults to get their influenza vaccine during National Influenza Vaccination Week
ACP is urging all adults to get vaccinated as influenza season, holiday gatherings, and winter weather are here, along with the continued presence of COVID-19 and respiratory syncytial virus.
https://immattersacp.org/weekly/archives/2023/12/05/5.htm
5 Dec 2023
Latest updates on ACP's priorities, initiatives
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, I.M. Matters Weekly from ACP.
https://immattersacp.org/archives/2024/01/latest-updates-on-acps-priorities-initiatives.htm
1 Jan 2024
CDC publishes recommendations on use of RSV vaccines
The two vaccines for respiratory syncytial virus (RSV) were approved by the FDA for older adults in May.
https://immattersacp.org/weekly/archives/2023/08/01/4.htm
1 Aug 2023
Busting COVID-19 vaccination myths
Misinformation and disinformation campaigns have contributed to the death toll of the COVID-19 pandemic. Internists can effectively counter this and encourage vaccinations.
https://immattersacp.org/archives/2021/11/busting-covid-19-vaccination-myths.htm
1 Nov 2021
Coadministration of zoster vaccine, COVID-19 booster appears safe, effective
An industry trial found that coadministration of an mRNA COVID-19 booster vaccine with a first dose of recombinant zoster vaccine was immunologically noninferior to spacing the shots two weeks apart, with a similar safety and reactogenicity profile.
https://immattersacp.org/weekly/archives/2023/06/27/2.htm
27 Jun 2023
New COVID-19 vaccines tested, authorization changes in progress for existing vaccines
The FDA further limited use of the Johnson & Johnson (Janssen) vaccine and scheduled advisory committee meetings on other vaccine questions. Two non-mRNA vaccines showed effectiveness, and other studies looked at antibody prevalence, home test accuracy, and long-term symptoms.
https://immattersacp.org/weekly/archives/2022/05/10/2.htm
10 May 2022
More clarity on myocarditis with mRNA COVID-19 vaccines
The classic presentation for COVID-19 vaccine-associated myocarditis is chest pain one to seven days after vaccination, with a median time of three days after vaccination, particularly after the second dose.
https://immattersacp.org/archives/2023/02/more-clarity-on-myocarditis-with-mrna-covid-19-vaccines.htm
1 Feb 2023
CDC reports on safety after month of COVID-19 vaccines, ACIP updates vaccine schedule
The 2021 schedule from the Advisory Committee on Immunization Practices (ACIP) includes interim recommendations for COVID-19 vaccination, as well as updates for vaccines against influenza, hepatitis A, and others.
https://immattersacp.org/weekly/archives/2021/02/23/3.htm
23 Feb 2021